Advertisement
YOU ARE HERE: LAT HomeCollectionsHepatitis C
IN THE NEWS

Hepatitis C

SCIENCE
April 18, 2003 | From Reuters
New experimental compounds may be able to help the body fight off hepatitis C -- an incurable virus that infects millions around the world and causes liver failure and cancer, researchers said Thursday. The research, done by separate teams in Canada and the United States, also led to discoveries about how hepatitis infects the body -- and how the body fights off infection. Hepatitis C was identified only in 1989.
Advertisement
CALIFORNIA | LOCAL
August 15, 1999 | PETER M. WARREN, TIMES STAFF WRITER
To many veterans, the cascade of scourges has a biblical quality: Post-traumatic stress disorder. Agent Orange. Birth defects. Gulf War syndrome. Now there is hepatitis C. The chronic liver ailment turns up in ex-service personnel who use VA facilities--especially Vietnam-era vets--at a rate four times the national average, medical experts say.
HEALTH
September 1, 2003 | Linda Marsa, Special to The Times
Of the millions of Americans infected with hepatitis C, only half respond to treatment. The others live with the constant threat that their health may suddenly, and fatally, deteriorate. A new drug could improve those odds. When used with the antiviral drug interferon, a medication called Zadaxin may help thousands of patients better fight the disease. "This medication looks promising for people who don't respond to other drugs," says Dr.
NEWS
May 14, 1995 | THOMAS H. MAUGH II, TIMES MEDICAL WRITER
The incidence of new hepatitis C infections among intravenous drug abusers has dropped unexpectedly by a dramatic 80% since 1990, according to preliminary results from the Centers for Disease Control and Prevention. Transmission of the virus among drug abusers is thought to account for as much as 85% of the hepatitis C infections discovered each year--a number that totaled 150,000 in 1990.
BUSINESS
June 17, 1998 | From Bloomberg News
Schering-Plough Corp. said Tuesday it is seeking U.S. regulatory approval to sell its combination hepatitis C therapy to a wider group of patients, including those who haven't been treated already with standard hepatitis-fighting drugs. The news follows an announcement last month that the combination of drugs developed by Schering-Plough and Costa Mesa-based ICN Pharmaceuticals Inc. offers significant benefits to previously untreated patients.
BUSINESS
August 9, 2001 | From Times Staff and Wire Reports
Schering-Plough Corp. said Wednesday it has received regulatory approval to sell two hepatitis C drugs in a combination package that's expected to become the new "gold standard" for treating a disease that affects 4 million Americans. The U.S. Food and Drug Administration said the New Jersey pharmaceuticals company can sell Peg-Intron, a longer-lasting form of its Intron A drug, in a single-package combination with its Rebetol drug from ICN Pharmaceuticals Inc. of Costa Mesa.
BUSINESS
December 10, 1998 | From Bloomberg News
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won regulatory approval Wednesday to sell their combination hepatitis C treatment to a wider group of patients. The Food and Drug Administration approved the combination therapy known as Rebetron for use in patients who haven't been treated already with standard hepatitis-fighting drugs. The wider use should boost sales for Schering-Plough, the eighth biggest U.S. drug maker, and Costa Mesa-based ICN, Eastern Europe's largest drug maker.
BUSINESS
August 17, 2001 | From Bloomberg News
ICN Pharmaceuticals Inc.'s ribavirin drug, used in combination with a Schering-Plough Corp. drug to treat hepatitis C, may face generic competition within a year if an unidentified company wins Food and Drug Administration approval for its version. The FDA's Web site said the agency has received a request from a company to sell a generic version of ribavirin, which is sold by Schering-Plough with its own hepatitis C drugs Intron A and Peg-Intron.
BUSINESS
June 4, 1998 | From Bloomberg News
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won Food and Drug Administration approval Wednesday to sell their combination treatment for hepatitis C patients who suffer a relapse. The combination includes Intron-A, which Schering-Plough already sells alone to treat hepatitis, and ICN's drug ribavirin, or Rebetol. Studies have shown the two drugs together provide a significant benefit to patients.
BUSINESS
June 4, 1998 | From Bloomberg News
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won U.S. Food and Drug Administration approval Wednesday to sell their combination treatment for hepatitis C patients who suffer a relapse. The combination includes Intron-A, which Schering-Plough already sells alone to treat hepatitis, and ICN's drug ribavirin, or Rebetol. Studies have shown the two drugs together provide a significant benefit to patients.
Los Angeles Times Articles
|